董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Eric W. Roberts | 男 | Director | 54 | 未披露 | 未持股 | 2018-04-19 |
| Daniel Wolterman | 男 | Director | 61 | 14.26万美元 | 未持股 | 2018-04-19 |
| Scott Flora | 男 | Director, Interim President and Chief Executive Officer | 62 | 16.51万美元 | 未持股 | 2018-04-19 |
| Eric W. Roberts | 男 | Director | 54 | 19.06万美元 | 未持股 | 2018-04-19 |
| William W. Burke | 男 | Director | 58 | 20.75万美元 | 未持股 | 2018-04-19 |
| Randall A. Lipps | 男 | Director | 60 | 19.65万美元 | 未持股 | 2018-04-19 |
| Gregory T. Lucier | 男 | Chairman and Director | 53 | 22.37万美元 | 未持股 | 2018-04-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Doug Heigel | 男 | Senior Vice President of Operations | 57 | 53.61万美元 | 未持股 | 2018-04-19 |
| Alex Vayser | 男 | Chief Technology Officer and Co-Founder | 50 | 未披露 | 未持股 | 2018-04-19 |
| Scott Flora | 男 | Director, Interim President and Chief Executive Officer | 62 | 16.51万美元 | 未持股 | 2018-04-19 |
| Marcia Fish | 女 | Chief Human Resources Officer | 54 | 未披露 | 未持股 | 2018-04-19 |
| Andrew Sale | 男 | Senior Vice President of Global Sales | 46 | 79.83万美元 | 未持股 | 2018-04-19 |
| Steven Annen | 男 | Vice President of Product Management and Strategy | 54 | 未披露 | 未持股 | 2018-04-19 |
| James H. Mackaness | 男 | Chief Financial Officer | 54 | 69.06万美元 | 未持股 | 2018-04-19 |
| Joseph Guido | 男 | Vice President of Business Development | 53 | 未披露 | 未持股 | 2018-04-19 |
董事简历
中英对照 | 中文 | 英文- Eric W. Roberts
-
Eric W. Roberts自2015年9月15日起担任公司董事。Roberts自2012年1月起担任Valence Life Sciences, LLC（一家生命科学资本投资公司）创始总经理。Roberts从2004年到2012年担任Caxton Advantage Venture Partners（一家投资公司）创始管理董事。Roberts从1986年到2004年担任多个投资银行家职位，包括担任Dillon, Read & Co. Inc.（一家投资银行，合并后成为UBS AG）生命科学部门总经理、合伙人和创始人；Lehman Brothers（一家全球服务金融公司）全齐医疗保健投资银行集团总经理和联合主管。Roberts现任Invuity, Inc.（一家公开上市医疗技术公司）和 Chinook Pharmaceuticals（一家制药公司）董事。他还从2007年开始担任Gemin X Pharmaceuticals, Inc.（一家生物技术公司）董事，一直担任到2011年该公司被Cephalon, Inc. 现名为Teva Pharmaceutical Industries Ltd.收购。Roberts持有University of Pennsylvania沃顿商学院经济学理学学士学位。
Eric W. Roberts,Mr. Roberts has served as a member of our board of directors since June 2012. Since January 2012 Mr. Roberts has been a founding Managing Director of Valence Life Sciences, and since 2017 Mr. Roberts has been a founding member of Valence Helix Investments. Additionally, since June 2006 Mr. Roberts has been a founding Managing Director of Caxton Advantage Venture Partners. From 1986 to 2004 Mr. Roberts served in a variety of roles as an investment banker, including as Managing Director and Partner at Dillon, Read & Co. and Managing Director and Co-Head of the Healthcare Investment Banking Group at Lehman Brothers. Mr. Roberts serves on the board of directors of VIVUS, Inc., a publicly traded biopharmaceutical company. Mr. Roberts received a B.S. in economics from the Wharton School of the University of Pennsylvania. - Eric W. Roberts自2015年9月15日起担任公司董事。Roberts自2012年1月起担任Valence Life Sciences, LLC（一家生命科学资本投资公司）创始总经理。Roberts从2004年到2012年担任Caxton Advantage Venture Partners（一家投资公司）创始管理董事。Roberts从1986年到2004年担任多个投资银行家职位，包括担任Dillon, Read & Co. Inc.（一家投资银行，合并后成为UBS AG）生命科学部门总经理、合伙人和创始人；Lehman Brothers（一家全球服务金融公司）全齐医疗保健投资银行集团总经理和联合主管。Roberts现任Invuity, Inc.（一家公开上市医疗技术公司）和 Chinook Pharmaceuticals（一家制药公司）董事。他还从2007年开始担任Gemin X Pharmaceuticals, Inc.（一家生物技术公司）董事，一直担任到2011年该公司被Cephalon, Inc. 现名为Teva Pharmaceutical Industries Ltd.收购。Roberts持有University of Pennsylvania沃顿商学院经济学理学学士学位。
- Eric W. Roberts,Mr. Roberts has served as a member of our board of directors since June 2012. Since January 2012 Mr. Roberts has been a founding Managing Director of Valence Life Sciences, and since 2017 Mr. Roberts has been a founding member of Valence Helix Investments. Additionally, since June 2006 Mr. Roberts has been a founding Managing Director of Caxton Advantage Venture Partners. From 1986 to 2004 Mr. Roberts served in a variety of roles as an investment banker, including as Managing Director and Partner at Dillon, Read & Co. and Managing Director and Co-Head of the Healthcare Investment Banking Group at Lehman Brothers. Mr. Roberts serves on the board of directors of VIVUS, Inc., a publicly traded biopharmaceutical company. Mr. Roberts received a B.S. in economics from the Wharton School of the University of Pennsylvania.
- Daniel Wolterman
-
Daniel Wolterman，Mr.Wolterman自2017年9月起担任我们的董事会成员。自2018年1月以来，Wolterman先生一直担任外科机器人公司Colubrismx，Inc.和血管内介入公司X-Cath，Inc.的首席执行官。自2016年8月1日起，Wolterman先生还担任Wolterman Consulting，LLC（一家为梦百合提供商和其他实体提供战略和运营咨询服务的公司）的唯一所有者兼首席执行官。从2002年到2016年，Wolterman先生担任Memorial Hermann Health System的总裁兼首席执行官，该公司是德克萨斯州的非营利医疗系统。Wolterman先生在医疗设备公司NuVasive，Inc.的董事会任职。此前，沃尔特曼曾在Volcano Corporation（Royal Philipps）董事会任职，该公司是一家医疗设备公司，2015年被Royal Philipps收购。Wolterman先生在辛辛那提大学（University of Cincinnati）获得工商管理学士学位和金融工商管理硕士学位，并在泽维尔大学（Xavier University）获得健康服务管理硕士学位。
Daniel Wolterman,Mr. Wolterman has served as a member of our board of directors since September 2017. Since January 2018 Mr. Wolterman has served as the Chief Executive Officer of ColubrisMX, Inc., a surgical robot company, and X-Cath, Inc., an endovascular interventional company. Since August 1 2016 Mr. Wolterman has also served as the sole owner and Chief Executive Officer of Wolterman Consulting, LLC, a company that provides strategic and operational consulting services to healthcare providers and other entities. From 2002 to 2016 Mr. Wolterman served as the President and Chief Executive Officer of Memorial Hermann Health System, a not-for-profit health system in Texas. Mr. Wolterman serves on the board of directors of NuVasive, Inc, a medical device company. Previously, Mr. Wolterman has served on the board of directors of Volcano Corporation, a medical device company acquired by Royal Philipps in 2015. Mr. Wolterman received both a B.S. in business administration and M.B.A. in finance from the University of Cincinnati, and a M.S. in Health Services Administration from Xavier University. - Daniel Wolterman，Mr.Wolterman自2017年9月起担任我们的董事会成员。自2018年1月以来，Wolterman先生一直担任外科机器人公司Colubrismx，Inc.和血管内介入公司X-Cath，Inc.的首席执行官。自2016年8月1日起，Wolterman先生还担任Wolterman Consulting，LLC（一家为梦百合提供商和其他实体提供战略和运营咨询服务的公司）的唯一所有者兼首席执行官。从2002年到2016年，Wolterman先生担任Memorial Hermann Health System的总裁兼首席执行官，该公司是德克萨斯州的非营利医疗系统。Wolterman先生在医疗设备公司NuVasive，Inc.的董事会任职。此前，沃尔特曼曾在Volcano Corporation（Royal Philipps）董事会任职，该公司是一家医疗设备公司，2015年被Royal Philipps收购。Wolterman先生在辛辛那提大学（University of Cincinnati）获得工商管理学士学位和金融工商管理硕士学位，并在泽维尔大学（Xavier University）获得健康服务管理硕士学位。
- Daniel Wolterman,Mr. Wolterman has served as a member of our board of directors since September 2017. Since January 2018 Mr. Wolterman has served as the Chief Executive Officer of ColubrisMX, Inc., a surgical robot company, and X-Cath, Inc., an endovascular interventional company. Since August 1 2016 Mr. Wolterman has also served as the sole owner and Chief Executive Officer of Wolterman Consulting, LLC, a company that provides strategic and operational consulting services to healthcare providers and other entities. From 2002 to 2016 Mr. Wolterman served as the President and Chief Executive Officer of Memorial Hermann Health System, a not-for-profit health system in Texas. Mr. Wolterman serves on the board of directors of NuVasive, Inc, a medical device company. Previously, Mr. Wolterman has served on the board of directors of Volcano Corporation, a medical device company acquired by Royal Philipps in 2015. Mr. Wolterman received both a B.S. in business administration and M.B.A. in finance from the University of Cincinnati, and a M.S. in Health Services Administration from Xavier University.
- Scott Flora
-
Scott Flora，弗洛拉先生自2018年3月起担任我们的临时总裁兼首席执行官，自2017年11月起担任我们的董事会成员。自2016年以来，Flora先生一直担任Sflora Consulting LLC（一家咨询公司）的总裁。Flora从2011年10月到2014年4月担任OmniGuide，Inc.（一家医疗设备公司）董事、总裁和首席执行官。从2006年11月到2011年6月，他曾担任Covidien plc（上市的全球梦百合产品公司，后被Medtronic plc收购）的手术器械部门的全球业务部门总裁。弗洛拉先生目前担任医疗器械公司Conventus Orthopaedics和骨健康医疗器械公司Agnovos梦百合的董事。此前，Flora先生曾任职于Mako SurgicalCorp.的董事会，该公司是一家医疗设备公司，于2013年12月被史赛克公司收购。Flora先生在米利金大学（Millikin University）获得营销学学士学位。
Scott Flora,Mr. Flora has served as our Interim President and Chief Executive Officer since March 2018 and a member of our board of directors since November 2017. Since 2016 Mr. Flora has served as the President of SFlora Consulting LLC, a consulting company. From October 2011 to April 2014 Mr. Flora served as the Director, President, and Chief Executive Officer of OmniGuide, Inc. a medical device company. From November 2006 to June 2011 he served as the Global Business Unit President for the surgical device division of Covidien plc, a publicly traded, global healthcare products company later acquired by Medtronic PLC. Mr. Flora currently serves on the board of directors of Conventus Orthopaedics, a medical device company, and AgNovos Healthcare, a bone health medical device company. Previously, Mr. Flora has served on the board of directors of MAKO Surgical Corp., a medical device company acquired by Stryker Corporation in December 2013. Mr. Flora received a B.S. in marketing from Millikin University. - Scott Flora，弗洛拉先生自2018年3月起担任我们的临时总裁兼首席执行官，自2017年11月起担任我们的董事会成员。自2016年以来，Flora先生一直担任Sflora Consulting LLC（一家咨询公司）的总裁。Flora从2011年10月到2014年4月担任OmniGuide，Inc.（一家医疗设备公司）董事、总裁和首席执行官。从2006年11月到2011年6月，他曾担任Covidien plc（上市的全球梦百合产品公司，后被Medtronic plc收购）的手术器械部门的全球业务部门总裁。弗洛拉先生目前担任医疗器械公司Conventus Orthopaedics和骨健康医疗器械公司Agnovos梦百合的董事。此前，Flora先生曾任职于Mako SurgicalCorp.的董事会，该公司是一家医疗设备公司，于2013年12月被史赛克公司收购。Flora先生在米利金大学（Millikin University）获得营销学学士学位。
- Scott Flora,Mr. Flora has served as our Interim President and Chief Executive Officer since March 2018 and a member of our board of directors since November 2017. Since 2016 Mr. Flora has served as the President of SFlora Consulting LLC, a consulting company. From October 2011 to April 2014 Mr. Flora served as the Director, President, and Chief Executive Officer of OmniGuide, Inc. a medical device company. From November 2006 to June 2011 he served as the Global Business Unit President for the surgical device division of Covidien plc, a publicly traded, global healthcare products company later acquired by Medtronic PLC. Mr. Flora currently serves on the board of directors of Conventus Orthopaedics, a medical device company, and AgNovos Healthcare, a bone health medical device company. Previously, Mr. Flora has served on the board of directors of MAKO Surgical Corp., a medical device company acquired by Stryker Corporation in December 2013. Mr. Flora received a B.S. in marketing from Millikin University.
- Eric W. Roberts
-
Eric W. Roberts，自2020年5月起担任CalciMedica首席商务官和董事会成员，并担任副董事长。自2012年以来，罗伯茨一直是Valence Life Sciences的创始董事总经理。罗伯茨先生还是Valence Investments SPV IV、Valence Investments SPV V和Valence Investments SPV VI的创始成员。此外，从2006年6月至2019年12月，罗伯茨先生担任Caxton Advantage Venture Partners的创始董事总经理。从2015年到2019年10月，罗伯茨在VIVUS，Inc.的董事会任职，该公司曾是一家上市生物制药公司。罗伯茨先生曾于2012年6月担任Invuity公司董事会成员，直至2018年10月将其出售给史赛克公司，并于2008年7月担任Gemin X Pharmaceuticals公司董事会成员，直至2012年3月将其出售给Cephalon, Inc.（现为梯瓦制药有限公司）。从1986年到2004年，罗伯茨担任过多种投资银行家的职务，包括2000年4月至2004年1月担任雷曼兄弟医疗保健投资银行部门联席主管，1989年4月至2000年4月担任Dillon，Read & Co. Inc.董事总经理兼合伙人，1986年6月至1989年4月担任花旗公司并购和风险投资部门成员。罗伯茨拥有宾夕法尼亚大学沃顿商学院经济学学士学位。
Eric W. Roberts,has served as CalciMedica's Chief Business Officer and a member of its board of directors since May 2020 and is vice chairman. Mr. Roberts has been a founding managing director of Valence Life Sciences since 2012. Mr. Roberts is also a founding member of Valence Investments SPV IV, Valence Investments SPV V and Valence Investments SPV VI. Additionally, from June 2006 to December 2019, Mr. Roberts served as a founding managing director of Caxton Advantage Venture Partners. From 2015 to October 2019, Mr. Roberts served on the board of directors of VIVUS, Inc., a former publicly traded biopharmaceutical company. Mr. Roberts previously served as a member of the board of directors of Invuity, Inc. from June 2012 until its sale to Stryker Corporation in October 2018 and as a member of the board of directors of Gemin X Pharmaceuticals, Inc. from July 2008 until its sale to Cephalon, Inc. (now Teva Pharmaceutical Industries Ltd.) in March 2012. From 1986 to 2004, Mr. Roberts served in a variety of roles as an investment banker, including as co-head of the healthcare investment banking group at Lehman Brothers from April 2000 to January 2004, managing director and partner at Dillon, Read & Co. Inc. from April 1989 to April 2000 and a member of Citicorp's mergers and venture capital groups from June 1986 to April 1989. Mr. Roberts holds a B.S. in Economics from The Wharton School of the University of Pennsylvania. - Eric W. Roberts，自2020年5月起担任CalciMedica首席商务官和董事会成员，并担任副董事长。自2012年以来，罗伯茨一直是Valence Life Sciences的创始董事总经理。罗伯茨先生还是Valence Investments SPV IV、Valence Investments SPV V和Valence Investments SPV VI的创始成员。此外，从2006年6月至2019年12月，罗伯茨先生担任Caxton Advantage Venture Partners的创始董事总经理。从2015年到2019年10月，罗伯茨在VIVUS，Inc.的董事会任职，该公司曾是一家上市生物制药公司。罗伯茨先生曾于2012年6月担任Invuity公司董事会成员，直至2018年10月将其出售给史赛克公司，并于2008年7月担任Gemin X Pharmaceuticals公司董事会成员，直至2012年3月将其出售给Cephalon, Inc.（现为梯瓦制药有限公司）。从1986年到2004年，罗伯茨担任过多种投资银行家的职务，包括2000年4月至2004年1月担任雷曼兄弟医疗保健投资银行部门联席主管，1989年4月至2000年4月担任Dillon，Read & Co. Inc.董事总经理兼合伙人，1986年6月至1989年4月担任花旗公司并购和风险投资部门成员。罗伯茨拥有宾夕法尼亚大学沃顿商学院经济学学士学位。
- Eric W. Roberts,has served as CalciMedica's Chief Business Officer and a member of its board of directors since May 2020 and is vice chairman. Mr. Roberts has been a founding managing director of Valence Life Sciences since 2012. Mr. Roberts is also a founding member of Valence Investments SPV IV, Valence Investments SPV V and Valence Investments SPV VI. Additionally, from June 2006 to December 2019, Mr. Roberts served as a founding managing director of Caxton Advantage Venture Partners. From 2015 to October 2019, Mr. Roberts served on the board of directors of VIVUS, Inc., a former publicly traded biopharmaceutical company. Mr. Roberts previously served as a member of the board of directors of Invuity, Inc. from June 2012 until its sale to Stryker Corporation in October 2018 and as a member of the board of directors of Gemin X Pharmaceuticals, Inc. from July 2008 until its sale to Cephalon, Inc. (now Teva Pharmaceutical Industries Ltd.) in March 2012. From 1986 to 2004, Mr. Roberts served in a variety of roles as an investment banker, including as co-head of the healthcare investment banking group at Lehman Brothers from April 2000 to January 2004, managing director and partner at Dillon, Read & Co. Inc. from April 1989 to April 2000 and a member of Citicorp's mergers and venture capital groups from June 1986 to April 1989. Mr. Roberts holds a B.S. in Economics from The Wharton School of the University of Pennsylvania.
- William W. Burke
-
William W. Burke，自2022年6月起担任Ceribell，Inc.董事会成员。从2015年11月到2024年6月担任Austin Highlands Advisors, LLC（企业咨询服务提供商）的总裁。2009年11月至2013年8月被Abbott Laboratories收购，他担任IDEV Technologies, Inc.（外围血管设备公司）的执行副总裁兼首席财务官。从2004年8月到2007年12月，他担任ReAble Therapeutics, Inc.的执行副总裁兼首席财务官，ReAble Therapeutics是一家多元化的骨科设备公司，于2006年出售给Blackstone Group进行私人交易，随后于2007年11月与DJO Incorporated合并。他一直在ReAble Therapeutics工作到2008年6月。从2001年到2004年，他担任Cholestech Corporation（医疗诊断产品公司）的首席财务官。他曾担任许多上市和私人公司的董事会成员，包括担任董事会主席和首席独立董事。他目前担任Nalu Medical（为慢性神经性疼痛患者提供微创解决方案的私人制造商）、Adtalem Global Education（医疗保健教育公司）和Tactile Systems Technology（为慢性疾病患者提供治疗的医疗技术公司）的董事会成员。他曾担任EQ Health Acquisition Corp.、Invuity, Inc.（2018年被Stryker Corporation收购）、LDR Holding Corporation（2016年被Zimmer Biomet收购）和Medical Action Industries Inc.（2014年被Owens & Minor收购）的董事会成员。他持有The University of Texas at Austin的金融学士学位和The Wharton School of The University of Pennsylvania的工商管理硕士学位。
William W. Burke has been a director of Adtalem since January 2017. He served as Adtalem Global Education Inc. Lead Independent Director from July 2019 through November 2022. From November 2015 to June 2024, Mr. Burke served as President of Atin Highlands Advisors, LLC, a provider of corporate advisory services. He served as Executive Vice President & Chief Financial Officer of IDEV Technologies, a peripheral vascular devices company, from November 2009 until the company was acquired by Abbott Laboratories in Augt 2013. From Augt 2004 to December 2007, he served as Executive Vice President & Chief Financial Officer of ReAble Therapeutics, a diversified orthopedic device company which was sold to The Blackstone Group in a going private transaction in 2006 and subsequently merged with DJO Incorporated in November 2007. Mr. Burke remained with ReAble Therapeutics until June 2008. From 2001 to 2004, he served as Chief Financial Officer of Cholestech Corporation, a medical diagnostic products company.Mr. Burke has served on numero public and private company boards including serving as a board chairman and a lead independent director. He has served on the board of Tactile Systems Technology, Inc. (NASDAQ: TCMD) since 2015 and currently serves as Chairman of the Board and as a member of its nominating and governance committee. Since 2022, he has served on the board of directors of Ceribell Inc., (NASDAQ: CBLL), a medical technology company. Mr. Burke also currently chairs Ceribell's audit committee and serves on the nominating and governance committee. In 2024, he joined the board of Nalu Medical, Inc., a privately held, medical technology company. He previoly served on the board of Invuity, Inc. (acquired by Stryker Corp. in 2018), LDR Holding Corporation (acquired by Zimmer Biomet in 2016), and Medical Action Indtries (acquired by Ons & Minor in 2014).Bachelor's degree in Finance from the University of Texas at Atin,MBA from the Wharton School of the University of Pennsylvania. - William W. Burke，自2022年6月起担任Ceribell，Inc.董事会成员。从2015年11月到2024年6月担任Austin Highlands Advisors, LLC（企业咨询服务提供商）的总裁。2009年11月至2013年8月被Abbott Laboratories收购，他担任IDEV Technologies, Inc.（外围血管设备公司）的执行副总裁兼首席财务官。从2004年8月到2007年12月，他担任ReAble Therapeutics, Inc.的执行副总裁兼首席财务官，ReAble Therapeutics是一家多元化的骨科设备公司，于2006年出售给Blackstone Group进行私人交易，随后于2007年11月与DJO Incorporated合并。他一直在ReAble Therapeutics工作到2008年6月。从2001年到2004年，他担任Cholestech Corporation（医疗诊断产品公司）的首席财务官。他曾担任许多上市和私人公司的董事会成员，包括担任董事会主席和首席独立董事。他目前担任Nalu Medical（为慢性神经性疼痛患者提供微创解决方案的私人制造商）、Adtalem Global Education（医疗保健教育公司）和Tactile Systems Technology（为慢性疾病患者提供治疗的医疗技术公司）的董事会成员。他曾担任EQ Health Acquisition Corp.、Invuity, Inc.（2018年被Stryker Corporation收购）、LDR Holding Corporation（2016年被Zimmer Biomet收购）和Medical Action Industries Inc.（2014年被Owens & Minor收购）的董事会成员。他持有The University of Texas at Austin的金融学士学位和The Wharton School of The University of Pennsylvania的工商管理硕士学位。
- William W. Burke has been a director of Adtalem since January 2017. He served as Adtalem Global Education Inc. Lead Independent Director from July 2019 through November 2022. From November 2015 to June 2024, Mr. Burke served as President of Atin Highlands Advisors, LLC, a provider of corporate advisory services. He served as Executive Vice President & Chief Financial Officer of IDEV Technologies, a peripheral vascular devices company, from November 2009 until the company was acquired by Abbott Laboratories in Augt 2013. From Augt 2004 to December 2007, he served as Executive Vice President & Chief Financial Officer of ReAble Therapeutics, a diversified orthopedic device company which was sold to The Blackstone Group in a going private transaction in 2006 and subsequently merged with DJO Incorporated in November 2007. Mr. Burke remained with ReAble Therapeutics until June 2008. From 2001 to 2004, he served as Chief Financial Officer of Cholestech Corporation, a medical diagnostic products company.Mr. Burke has served on numero public and private company boards including serving as a board chairman and a lead independent director. He has served on the board of Tactile Systems Technology, Inc. (NASDAQ: TCMD) since 2015 and currently serves as Chairman of the Board and as a member of its nominating and governance committee. Since 2022, he has served on the board of directors of Ceribell Inc., (NASDAQ: CBLL), a medical technology company. Mr. Burke also currently chairs Ceribell's audit committee and serves on the nominating and governance committee. In 2024, he joined the board of Nalu Medical, Inc., a privately held, medical technology company. He previoly served on the board of Invuity, Inc. (acquired by Stryker Corp. in 2018), LDR Holding Corporation (acquired by Zimmer Biomet in 2016), and Medical Action Indtries (acquired by Ons & Minor in 2014).Bachelor's degree in Finance from the University of Texas at Atin,MBA from the Wharton School of the University of Pennsylvania.
- Randall A. Lipps
-
Randall A. Lipps，自从1992年9月Omnicell成立以来，他担任董事长和董事。自2002年10月以来，他担任其总裁兼首席执行官。从1989年到1992年，他担任ST.Holdings, Inc.（一个旅游和营销公司）的高级副总裁。从1987年到1989年，他担任AMR的子公司和美国航空公司（American Airlines, Inc.）的助理副总裁负责销售和运营。他获得南卫理公会大学（Southern Methodist University）的经济学学士学位和工商管理学士学位。
Randall A. Lipps,has served as Chairman of the Board and a director of Omnicell since founding Omnicell in September 1992, and as its President and Chief Executive Officer since October 2002. From June 2013 to October 2018, Mr. Lipps was a director of Invuity, Inc., a medical device company. Mr. Lipps serves as a member of the Board of Trustees of the American Nurses Foundation. Mr. Lipps received both a B.S. in economics and a B.B.A. from Southern Methodist University. - Randall A. Lipps，自从1992年9月Omnicell成立以来，他担任董事长和董事。自2002年10月以来，他担任其总裁兼首席执行官。从1989年到1992年，他担任ST.Holdings, Inc.（一个旅游和营销公司）的高级副总裁。从1987年到1989年，他担任AMR的子公司和美国航空公司（American Airlines, Inc.）的助理副总裁负责销售和运营。他获得南卫理公会大学（Southern Methodist University）的经济学学士学位和工商管理学士学位。
- Randall A. Lipps,has served as Chairman of the Board and a director of Omnicell since founding Omnicell in September 1992, and as its President and Chief Executive Officer since October 2002. From June 2013 to October 2018, Mr. Lipps was a director of Invuity, Inc., a medical device company. Mr. Lipps serves as a member of the Board of Trustees of the American Nurses Foundation. Mr. Lipps received both a B.S. in economics and a B.B.A. from Southern Methodist University.
- Gregory T. Lucier
-
Gregory T. Lucier，他一直担任董事会成员（2015年4月以来）。Lucier先生是Corza Health， Inc.（自2019年4月以来专注于收购医疗保健公司和资产的公司）的首席执行官。在此之前，他曾担任NuVasive， Inc.（医疗器械公司）的董事长兼首席执行官（2015年至2018年）。加入NuVasive之前，Lucier先生从2003年5月起担任Life Technologies Corporation（一家全球生物技术公司）的董事长兼首席执行官，直到该公司于2014年2月被Thermo Fisher Scientific Inc.收购。在此之前，Lucier先生是通用电气公司的公司官员，在那里他担任各种领导职务。Lucier先生是Dentsply Sirona的董事长和Maravai LifeSciences的董事。此前，他曾担任Life Technologies Corporation（2003年5月至2014年2月）、Carefusion Corporation（2009年8月至2015年3月出售给Becton Dickinson）、Invuity, inc（2014年10月至2018年10月出售给Stryker）和Nuvasive（2013年12月至2021年5月）的董事。他持有Harvard Business School的工商管理硕士学位和Pennsylvania State大学的工业工程学士学位。
Gregory T. Lucier,has been a member of the Board since April 2015. Mr. Lucier is the chief executive officer of Corza Health, Inc. a company focused on acquiring healthcare companies and assets since April 2019. Prior to that, he served as Chairman and Chief Executive Officer of NuVasive, Inc., a medical device company, from 2015 to 2018. Before joining NuVasive, Mr. Lucier was Chairman and Chief Executive Officer of Life Technologies Corporation, a global biotechnology company, from May 2003 until it was acquired by Thermo Fisher Scientific Inc. in February 2014. Prior to that, Mr. Lucier was a corporate officer at General Electric Company, where he served in a variety of leadership roles. Mr. Lucier is chairman of Dentsply Sirona and a director at Maravai LifeSciences. He previously served as a director of Life Technologies Corporation from May 2003 to February 2014, of Carefusion Corporation from August 2009 until its sale to Becton Dickinson in March 2015, of Invuity, Inc. from October 2014 until its sale to Stryker in October 2018, and of Nuvasive from December 2013 to May 2021. Mr. Lucier received an M.B.A. from Harvard Business School and a B.S. in industrial engineering from Pennsylvania State University. - Gregory T. Lucier，他一直担任董事会成员（2015年4月以来）。Lucier先生是Corza Health， Inc.（自2019年4月以来专注于收购医疗保健公司和资产的公司）的首席执行官。在此之前，他曾担任NuVasive， Inc.（医疗器械公司）的董事长兼首席执行官（2015年至2018年）。加入NuVasive之前，Lucier先生从2003年5月起担任Life Technologies Corporation（一家全球生物技术公司）的董事长兼首席执行官，直到该公司于2014年2月被Thermo Fisher Scientific Inc.收购。在此之前，Lucier先生是通用电气公司的公司官员，在那里他担任各种领导职务。Lucier先生是Dentsply Sirona的董事长和Maravai LifeSciences的董事。此前，他曾担任Life Technologies Corporation（2003年5月至2014年2月）、Carefusion Corporation（2009年8月至2015年3月出售给Becton Dickinson）、Invuity, inc（2014年10月至2018年10月出售给Stryker）和Nuvasive（2013年12月至2021年5月）的董事。他持有Harvard Business School的工商管理硕士学位和Pennsylvania State大学的工业工程学士学位。
- Gregory T. Lucier,has been a member of the Board since April 2015. Mr. Lucier is the chief executive officer of Corza Health, Inc. a company focused on acquiring healthcare companies and assets since April 2019. Prior to that, he served as Chairman and Chief Executive Officer of NuVasive, Inc., a medical device company, from 2015 to 2018. Before joining NuVasive, Mr. Lucier was Chairman and Chief Executive Officer of Life Technologies Corporation, a global biotechnology company, from May 2003 until it was acquired by Thermo Fisher Scientific Inc. in February 2014. Prior to that, Mr. Lucier was a corporate officer at General Electric Company, where he served in a variety of leadership roles. Mr. Lucier is chairman of Dentsply Sirona and a director at Maravai LifeSciences. He previously served as a director of Life Technologies Corporation from May 2003 to February 2014, of Carefusion Corporation from August 2009 until its sale to Becton Dickinson in March 2015, of Invuity, Inc. from October 2014 until its sale to Stryker in October 2018, and of Nuvasive from December 2013 to May 2021. Mr. Lucier received an M.B.A. from Harvard Business School and a B.S. in industrial engineering from Pennsylvania State University.
高管简历
中英对照 | 中文 | 英文- Doug Heigel
Doug Heigel自2014年9月起担任公司运营副总裁。Heigel从2003年7月到2014年1月担任Solta Medical（一家医疗美学公司，2014年1月被Valeant Pharmaceuticals收购）运营副总裁。Heigel于2002年5月加入Solta Medical的前身公司Thermage担任运营高级主管。Heigel于1995年10月到2002年2月在Argonaut Technologies（一家生物技术公司）任职，首先担任制造主管，后来担任制造副总裁。加入Argonaut之前，Heigel曾在半导体和测量仪器市场担任多个运营和技术领导职位。Heigel持有Oregon State University机械工程理学学士学位。
Doug Heigel has served as our Senior Vice President of Operations since September 2017 and our Vice President of Operations since September 2014. From July 2003 to January 2014 Mr. Heigel served as Vice President of Operations for Solta Medical, a medical aesthetics company which was sold to Valeant Pharmaceuticals in January 2014. In May 2002 Mr. Heigel joined Solta Medical's predecessor company, Thermage, as Senior Director of Operations. From October 1995 to February 2002 Mr. Heigel worked for Argonaut Technologies, a life sciences company, first as Director of Manufacturing and then as Vice President of Manufacturing. Prior to Argonaut, Mr. Heigel served in various operational and technical leadership roles in the semiconductor and measurement instrumentation markets. Mr. Heigel received a B.S. in mechanical engineering from Oregon State University.- Doug Heigel自2014年9月起担任公司运营副总裁。Heigel从2003年7月到2014年1月担任Solta Medical（一家医疗美学公司，2014年1月被Valeant Pharmaceuticals收购）运营副总裁。Heigel于2002年5月加入Solta Medical的前身公司Thermage担任运营高级主管。Heigel于1995年10月到2002年2月在Argonaut Technologies（一家生物技术公司）任职，首先担任制造主管，后来担任制造副总裁。加入Argonaut之前，Heigel曾在半导体和测量仪器市场担任多个运营和技术领导职位。Heigel持有Oregon State University机械工程理学学士学位。
- Doug Heigel has served as our Senior Vice President of Operations since September 2017 and our Vice President of Operations since September 2014. From July 2003 to January 2014 Mr. Heigel served as Vice President of Operations for Solta Medical, a medical aesthetics company which was sold to Valeant Pharmaceuticals in January 2014. In May 2002 Mr. Heigel joined Solta Medical's predecessor company, Thermage, as Senior Director of Operations. From October 1995 to February 2002 Mr. Heigel worked for Argonaut Technologies, a life sciences company, first as Director of Manufacturing and then as Vice President of Manufacturing. Prior to Argonaut, Mr. Heigel served in various operational and technical leadership roles in the semiconductor and measurement instrumentation markets. Mr. Heigel received a B.S. in mechanical engineering from Oregon State University.
- Alex Vayser
Alex Vayser，联合创立了Invuity，自2004年11月起担任首席技术官。加入Invuity之前，Vayser联合创立了Medvision（一家定制手术内窥镜和成像设备制造商），并担任其总裁。在Medvision任职期间，Vayser联合创立了Parallax Devices（一家专注于医疗和工业应用单通道立体和三维光学系统的公司）。Vayser持有the University of Rochester's Institute of Optics光学工程理学学士学位。
Alex Vayser co-founded Invuity and has served as our Chief Technology Officer since November 2004. Prior to joining Invuity, Mr. Vayser co-founded and served as President of Medvision, a manufacturer of custom surgical endoscopes and imaging devices. While at Medvision, Mr. Vayser co-founded Parallax Devices, a company focused on single channel stereoscopic and 3-D optical systems for medical and industrial applications. Mr. Vayser received a B.S. in optical engineering from the University of Rochester's Institute of Optics.- Alex Vayser，联合创立了Invuity，自2004年11月起担任首席技术官。加入Invuity之前，Vayser联合创立了Medvision（一家定制手术内窥镜和成像设备制造商），并担任其总裁。在Medvision任职期间，Vayser联合创立了Parallax Devices（一家专注于医疗和工业应用单通道立体和三维光学系统的公司）。Vayser持有the University of Rochester's Institute of Optics光学工程理学学士学位。
- Alex Vayser co-founded Invuity and has served as our Chief Technology Officer since November 2004. Prior to joining Invuity, Mr. Vayser co-founded and served as President of Medvision, a manufacturer of custom surgical endoscopes and imaging devices. While at Medvision, Mr. Vayser co-founded Parallax Devices, a company focused on single channel stereoscopic and 3-D optical systems for medical and industrial applications. Mr. Vayser received a B.S. in optical engineering from the University of Rochester's Institute of Optics.
- Scott Flora
Scott Flora，弗洛拉先生自2018年3月起担任我们的临时总裁兼首席执行官，自2017年11月起担任我们的董事会成员。自2016年以来，Flora先生一直担任Sflora Consulting LLC（一家咨询公司）的总裁。Flora从2011年10月到2014年4月担任OmniGuide，Inc.（一家医疗设备公司）董事、总裁和首席执行官。从2006年11月到2011年6月，他曾担任Covidien plc（上市的全球梦百合产品公司，后被Medtronic plc收购）的手术器械部门的全球业务部门总裁。弗洛拉先生目前担任医疗器械公司Conventus Orthopaedics和骨健康医疗器械公司Agnovos梦百合的董事。此前，Flora先生曾任职于Mako SurgicalCorp.的董事会，该公司是一家医疗设备公司，于2013年12月被史赛克公司收购。Flora先生在米利金大学（Millikin University）获得营销学学士学位。
Scott Flora,Mr. Flora has served as our Interim President and Chief Executive Officer since March 2018 and a member of our board of directors since November 2017. Since 2016 Mr. Flora has served as the President of SFlora Consulting LLC, a consulting company. From October 2011 to April 2014 Mr. Flora served as the Director, President, and Chief Executive Officer of OmniGuide, Inc. a medical device company. From November 2006 to June 2011 he served as the Global Business Unit President for the surgical device division of Covidien plc, a publicly traded, global healthcare products company later acquired by Medtronic PLC. Mr. Flora currently serves on the board of directors of Conventus Orthopaedics, a medical device company, and AgNovos Healthcare, a bone health medical device company. Previously, Mr. Flora has served on the board of directors of MAKO Surgical Corp., a medical device company acquired by Stryker Corporation in December 2013. Mr. Flora received a B.S. in marketing from Millikin University.- Scott Flora，弗洛拉先生自2018年3月起担任我们的临时总裁兼首席执行官，自2017年11月起担任我们的董事会成员。自2016年以来，Flora先生一直担任Sflora Consulting LLC（一家咨询公司）的总裁。Flora从2011年10月到2014年4月担任OmniGuide，Inc.（一家医疗设备公司）董事、总裁和首席执行官。从2006年11月到2011年6月，他曾担任Covidien plc（上市的全球梦百合产品公司，后被Medtronic plc收购）的手术器械部门的全球业务部门总裁。弗洛拉先生目前担任医疗器械公司Conventus Orthopaedics和骨健康医疗器械公司Agnovos梦百合的董事。此前，Flora先生曾任职于Mako SurgicalCorp.的董事会，该公司是一家医疗设备公司，于2013年12月被史赛克公司收购。Flora先生在米利金大学（Millikin University）获得营销学学士学位。
- Scott Flora,Mr. Flora has served as our Interim President and Chief Executive Officer since March 2018 and a member of our board of directors since November 2017. Since 2016 Mr. Flora has served as the President of SFlora Consulting LLC, a consulting company. From October 2011 to April 2014 Mr. Flora served as the Director, President, and Chief Executive Officer of OmniGuide, Inc. a medical device company. From November 2006 to June 2011 he served as the Global Business Unit President for the surgical device division of Covidien plc, a publicly traded, global healthcare products company later acquired by Medtronic PLC. Mr. Flora currently serves on the board of directors of Conventus Orthopaedics, a medical device company, and AgNovos Healthcare, a bone health medical device company. Previously, Mr. Flora has served on the board of directors of MAKO Surgical Corp., a medical device company acquired by Stryker Corporation in December 2013. Mr. Flora received a B.S. in marketing from Millikin University.
- Marcia Fish
Marcia Fish自2017年10月起担任我们的首席人力资源官。在加入我们之前，Fish女士于2014年至2017年担任私募股权公司Marlin Equity Partners的首席人力资源官。Fish从1990年到2013年在General Electric（一家跨国企业集团）担任多个职责递增的职位，包括担任多个美国和美国以外业务人力资源主管。Fish女士在康奈尔大学（Cornell University）获得劳资关系学士学位，并在杜克大学（Duke University）福库商学院（Fuqua School of Business）获得工商管理硕士学位。
Marcia Fish has served as our Chief Human Resources Officer since October 2017. Prior to joining us, Ms. Fish served as Chief Human Resources Officer of Marlin Equity Partners, a private equity firm, from 2014 to 2017. From 1990 to 2013 Ms. Fish served in a number of roles of increasing responsibility at General Electric, a multinational conglomerate, including serving as Human Resources lead for several U.S. and ex-U.S. businesses. Ms. Fish received a B.A. in Industrial and Labor Relations from Cornell University and an M.B.A. from Duke University's Fuqua School of Business.- Marcia Fish自2017年10月起担任我们的首席人力资源官。在加入我们之前，Fish女士于2014年至2017年担任私募股权公司Marlin Equity Partners的首席人力资源官。Fish从1990年到2013年在General Electric（一家跨国企业集团）担任多个职责递增的职位，包括担任多个美国和美国以外业务人力资源主管。Fish女士在康奈尔大学（Cornell University）获得劳资关系学士学位，并在杜克大学（Duke University）福库商学院（Fuqua School of Business）获得工商管理硕士学位。
- Marcia Fish has served as our Chief Human Resources Officer since October 2017. Prior to joining us, Ms. Fish served as Chief Human Resources Officer of Marlin Equity Partners, a private equity firm, from 2014 to 2017. From 1990 to 2013 Ms. Fish served in a number of roles of increasing responsibility at General Electric, a multinational conglomerate, including serving as Human Resources lead for several U.S. and ex-U.S. businesses. Ms. Fish received a B.A. in Industrial and Labor Relations from Cornell University and an M.B.A. from Duke University's Fuqua School of Business.
- Andrew Sale
Andrew Sale自2017年1月起担任我们的全球销售高级副总裁。在加入我们之前，Sale先生于2015年8月至2016年6月担任Alpha Genomix Laboratories的Vice President。Sale从2004年4月到2014年12月在Intuitive Surgical（一家机器人手术系统上市制造商）担任多个职位，包括销售经理、地区Vice President销售总监、地区Vice President，最后的职位是负责所有美国资本业务。在加入Intuitive Surgical之前，Sale先生在强生公司工作了6年，在那里他在Ethicon内部的主要专业公司提供销售和销售领导，以推动新兴产品的增长。Sale先生在路易斯安那州立大学（Louisiana State University）获得通识研究学士学位。
Andrew Sale has served as our Senior Vice President of Global Sales since January of 2017. Prior to joining us, Mr. Sale served as Vice President at Alpha Genomix Laboratories from August 2015 to June 2016. From April 2004 to December 2014 Mr. Sale served in a variety of roles at Intuitive Surgical, a publicly traded manufacturer of robotic surgical systems, including Sales Manager, Sales Director, Area Vice President, Regional Vice President and in his last role was responsible for all the U.S. capital business. Prior to Intuitive Surgical, Mr. Sale spent six years at Johnson & Johnson, where he provided sales and sales leadership in key specialty companies inside of Ethicon to drive the growth of emerging products. Mr. Sale received a B.A. in General Studies from Louisiana State University.- Andrew Sale自2017年1月起担任我们的全球销售高级副总裁。在加入我们之前，Sale先生于2015年8月至2016年6月担任Alpha Genomix Laboratories的Vice President。Sale从2004年4月到2014年12月在Intuitive Surgical（一家机器人手术系统上市制造商）担任多个职位，包括销售经理、地区Vice President销售总监、地区Vice President，最后的职位是负责所有美国资本业务。在加入Intuitive Surgical之前，Sale先生在强生公司工作了6年，在那里他在Ethicon内部的主要专业公司提供销售和销售领导，以推动新兴产品的增长。Sale先生在路易斯安那州立大学（Louisiana State University）获得通识研究学士学位。
- Andrew Sale has served as our Senior Vice President of Global Sales since January of 2017. Prior to joining us, Mr. Sale served as Vice President at Alpha Genomix Laboratories from August 2015 to June 2016. From April 2004 to December 2014 Mr. Sale served in a variety of roles at Intuitive Surgical, a publicly traded manufacturer of robotic surgical systems, including Sales Manager, Sales Director, Area Vice President, Regional Vice President and in his last role was responsible for all the U.S. capital business. Prior to Intuitive Surgical, Mr. Sale spent six years at Johnson & Johnson, where he provided sales and sales leadership in key specialty companies inside of Ethicon to drive the growth of emerging products. Mr. Sale received a B.A. in General Studies from Louisiana State University.
- Steven Annen
Steven Annen自2016年4月起担任我们的产品管理和战略Vice President。他于2015年11月加入公司，担任高级董事，负责产品管理和战略。Annen从2014年1月到2015年10月担任Grabit，Inc.（一家材料处理技术供应商）营销Vice President。Annen从2005年10月到2014年1月担任Intuitive Surgical Inc.（一家机器人手术系统上市制造商）产品营销主管。任职Intuitive Surgical公司之前，Annen先生曾担任公共部门公司的领导职务，包括Veeco Instruments，Inc.（流程设备技术的公开交易供应商）和Adept Technology Inc.（智能视觉引导机器人系统和服务的公开交易供应商）。Annen先生在罗格斯大学（Rutgers University）获得机械工程学士学位，并在麦迪逊威斯康星大学（University of Wisconsin，Madison）获得机械工程硕士学位。
Steven Annen has served as our Vice President of Product Management and Strategy since April 2016. He joined the Company in November 2015 as Senior Director, Product Management and Strategy. From January 2014 to October 2015 Mr. Annen served as the Vice President of Marketing for Grabit, Inc., a material handling technology provider. From October 2005 to January 2014 Mr. Annen served as the Director of Product Marketing at Intuitive Surgical Inc., a publicly traded manufacturer of robotic surgical systems. Prior to Intuitive Surgical, Mr. Annen held leadership roles in public sector companies including Veeco Instruments, Inc., a publicly traded provider of process equipment technology, and Adept Technology Inc., a publicly traded provider of intelligent vision-guided robotics systems and services. Mr. Annen received his B.S. in mechanical engineering from Rutgers University and his M.S. in mechanical engineering from the University of Wisconsin, Madison.- Steven Annen自2016年4月起担任我们的产品管理和战略Vice President。他于2015年11月加入公司，担任高级董事，负责产品管理和战略。Annen从2014年1月到2015年10月担任Grabit，Inc.（一家材料处理技术供应商）营销Vice President。Annen从2005年10月到2014年1月担任Intuitive Surgical Inc.（一家机器人手术系统上市制造商）产品营销主管。任职Intuitive Surgical公司之前，Annen先生曾担任公共部门公司的领导职务，包括Veeco Instruments，Inc.（流程设备技术的公开交易供应商）和Adept Technology Inc.（智能视觉引导机器人系统和服务的公开交易供应商）。Annen先生在罗格斯大学（Rutgers University）获得机械工程学士学位，并在麦迪逊威斯康星大学（University of Wisconsin，Madison）获得机械工程硕士学位。
- Steven Annen has served as our Vice President of Product Management and Strategy since April 2016. He joined the Company in November 2015 as Senior Director, Product Management and Strategy. From January 2014 to October 2015 Mr. Annen served as the Vice President of Marketing for Grabit, Inc., a material handling technology provider. From October 2005 to January 2014 Mr. Annen served as the Director of Product Marketing at Intuitive Surgical Inc., a publicly traded manufacturer of robotic surgical systems. Prior to Intuitive Surgical, Mr. Annen held leadership roles in public sector companies including Veeco Instruments, Inc., a publicly traded provider of process equipment technology, and Adept Technology Inc., a publicly traded provider of intelligent vision-guided robotics systems and services. Mr. Annen received his B.S. in mechanical engineering from Rutgers University and his M.S. in mechanical engineering from the University of Wisconsin, Madison.
- James H. Mackaness
James H. Mackaness，2008年1月，他加入公司，担任首席财务官；自2012年8月起，他担任公司首席运营官。在该公司任职之前，自2001年9月至2007年12月，他担任NextHop Technologies, Inc.（一个网络无线技术公司）的首席财务官和财务部门副总裁。在那之前，他担任 Infogear Technologies Corporation的财务部门副总裁和首席财务官；并在 Cisco Systems, Inc. 和 Ernst & Young LLP。担任过管理方面的职务。他以优秀成绩取得英国the University of Warwick心理学学士学位，是一名特许会计师，以及是the Institute of Chartered Accountants of England and Wales。的成员。
James H. Mackaness has served as our Chief Financial Officer since August 2015. Prior to joining us, Mr. Mackaness served as Chief Financial Officer and Chief Operating Officer of IRIDEX Corporation, a medical device company, from August 2012 to August 2015 and as Chief Financial Officer from Jan 2008 to August 2012. From September 2001 to December 2007 Mr. Mackaness served as Chief Financial Officer and Vice President of Finance of NextHop Technologies, Inc., a networking wireless technology company. Prior to that, Mr. Mackaness served as Chief Financial Officer and Vice President of Finance of Infogear Technologies Corporation and held management positions at Cisco Systems, Inc., Electroglas, Inc. and Ernst & Young LLP. Mr. Mackaness received a B.A. with honors in Psychology from the University of Warwick, England and is a Chartered Accountant and member of the Institute of Chartered Accountants of England and Wales.- James H. Mackaness，2008年1月，他加入公司，担任首席财务官；自2012年8月起，他担任公司首席运营官。在该公司任职之前，自2001年9月至2007年12月，他担任NextHop Technologies, Inc.（一个网络无线技术公司）的首席财务官和财务部门副总裁。在那之前，他担任 Infogear Technologies Corporation的财务部门副总裁和首席财务官；并在 Cisco Systems, Inc. 和 Ernst & Young LLP。担任过管理方面的职务。他以优秀成绩取得英国the University of Warwick心理学学士学位，是一名特许会计师，以及是the Institute of Chartered Accountants of England and Wales。的成员。
- James H. Mackaness has served as our Chief Financial Officer since August 2015. Prior to joining us, Mr. Mackaness served as Chief Financial Officer and Chief Operating Officer of IRIDEX Corporation, a medical device company, from August 2012 to August 2015 and as Chief Financial Officer from Jan 2008 to August 2012. From September 2001 to December 2007 Mr. Mackaness served as Chief Financial Officer and Vice President of Finance of NextHop Technologies, Inc., a networking wireless technology company. Prior to that, Mr. Mackaness served as Chief Financial Officer and Vice President of Finance of Infogear Technologies Corporation and held management positions at Cisco Systems, Inc., Electroglas, Inc. and Ernst & Young LLP. Mr. Mackaness received a B.A. with honors in Psychology from the University of Warwick, England and is a Chartered Accountant and member of the Institute of Chartered Accountants of England and Wales.
- Joseph Guido
Joseph Guido在2012年4月作为市场营销和业务发展部的副总裁加入Hansen。在加入Hansen先生，在2011年7月到2011年11月期间，Guido先生曾担任Heartstitch Medical（一家医疗设备公司）的总裁。在2006年5月到2010年10月期间，Guido先生曾是Novare Surgical Systems, Inc.（一家私营医疗设备公司，主要开发微创开发手术方面的产品）的销售和市场营销部副总裁。在Novare之前，他曾是Abbott Vascular Devices的血管闭塞相关产品业务的全球市场营销战略部的主任和Intuitive Surgical（一家上市的医疗设备公司，专注于外科手术机器系统的研发）的全球市场营销部副总裁。Guido先生拥有维拉诺瓦大学（Villanova University ）的工商管理理学士学位和佩波戴恩大学（Pepperdine University）的工商管理硕士学位。
Joseph Guido has served as our Vice President of Business Development since February 2016. From 2012 to 2016 Mr. Guido served as Senior Vice President of Marketing and Business Development for Hansen Medical, a publicly-traded robotics company in the vascular and cardiac sectors. Prior to joining Hansen Medical, Mr. Guido served as the President of Heartstitch Medical, a medical devices company, in 2011. Prior to joining Heartstitch Medical, Mr. Guido held a variety of leadership roles in Marketing, Sales and Business Development for both public and private medical device companies such as Stryker Endoscopy, Intuitive Surgical, Novare Surgical and Abbott Vascular Devices. Mr. Guido received his B.S. degree in business administration from Villanova University and his M.B.A. from Pepperdine University.- Joseph Guido在2012年4月作为市场营销和业务发展部的副总裁加入Hansen。在加入Hansen先生，在2011年7月到2011年11月期间，Guido先生曾担任Heartstitch Medical（一家医疗设备公司）的总裁。在2006年5月到2010年10月期间，Guido先生曾是Novare Surgical Systems, Inc.（一家私营医疗设备公司，主要开发微创开发手术方面的产品）的销售和市场营销部副总裁。在Novare之前，他曾是Abbott Vascular Devices的血管闭塞相关产品业务的全球市场营销战略部的主任和Intuitive Surgical（一家上市的医疗设备公司，专注于外科手术机器系统的研发）的全球市场营销部副总裁。Guido先生拥有维拉诺瓦大学（Villanova University ）的工商管理理学士学位和佩波戴恩大学（Pepperdine University）的工商管理硕士学位。
- Joseph Guido has served as our Vice President of Business Development since February 2016. From 2012 to 2016 Mr. Guido served as Senior Vice President of Marketing and Business Development for Hansen Medical, a publicly-traded robotics company in the vascular and cardiac sectors. Prior to joining Hansen Medical, Mr. Guido served as the President of Heartstitch Medical, a medical devices company, in 2011. Prior to joining Heartstitch Medical, Mr. Guido held a variety of leadership roles in Marketing, Sales and Business Development for both public and private medical device companies such as Stryker Endoscopy, Intuitive Surgical, Novare Surgical and Abbott Vascular Devices. Mr. Guido received his B.S. degree in business administration from Villanova University and his M.B.A. from Pepperdine University.